---
title: BT-474 Orthotopic Model - TD2 Precision Oncology
description: BT-474 is a HER2-positive mammary ductal carcinoma cell line, instrumental for research on breast cancer biology and therapeutic developments.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/bt-474.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# BT-474 Orthotopic Model
**Synonyms:** BT474
BT-474 is a cell line sourced from human mammary ductal carcinoma, more commonly known as breast cancer. Renowned for its expression of the human epidermal growth factor receptor 2 (HER2), it provides a robust model for the study of HER2-positive breast cancers. BT-474 showcases vital molecular and genetic signatures typical of specific breast cancer subtypes, ensuring its relevance in both in vitro and in vivo research initiatives. The behavior of this cell line, including its proliferative rates, hormone responsiveness, and resistance patterns, mirrors many of the clinical presentations of HER2-positive breast tumors. Utilized globally, BT-474 is pivotal for researchers aiming to deepen their understanding of breast cancer pathogenesis, as well as for those working towards the optimization of targeted therapies.
## Model Details
**Cancer Type:** Breast Cancer
**Model Name:** BT-474
**Mouse Strain:** Nu/Nu
**Treatment Data Available:** N/A
## BT-474 Growth curves
Growth of orthotopic (MFP) BT-474 in Nu/Nu mice (n=5)
### Request Additional Syngeneic Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)